The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prevalence of KIT Expression in Human Tumors
Open accessAbstract
Purpose: KIT is a target for imatinib mesylate (Gleevec; Novartis Pharma, Basel, Switzerland). Gastrointestinal stromal tumors (GISTs) express KIT and respond favorably to imatinib therapy. To determine other tumors in which such a molecular targeted therapy might be indicated, we investigated KIT expression in different human tumor types. Because recent studies in GISTs suggest that KIT-activating mutations predict response to imatinib therapy, we also sequenced a subset of positive tumors. Materials and Methods: More than 3,000 tumors from more than 120 different tumor categories were analyzed by immunohistochemistry in a tissue microarray format. Seven commercially available anti-KIT antibodies were initially evaluated. The antibody A4502 (DAKO) was selected for analysis because of a high frequency of positivity in GIST and low staining background in other tissues. To determine the frequency of KIT mutations in various tumor types, the exons 2, 8, 9, 11, 13, and 17 (where mutations previously were reported) were sequenced in 36 tumors with strong KIT expression. Results: KIT positivity was detected in 28 of 28 GISTs (100%), 42 of 50 seminomas (84%), 34 of 52 adenoid-cystic carcinomas (65%), 14 of 39 malignant melanomas (35%), and eight of 47 large-cell carcinomas of the lung (17%), as well as in 47 additional tumor types. KIT mutations were found in six of 12 analyzed GISTs, but only in one of 24 other tumors. Conclusion: The results suggest that KIT expression occurs infrequently in most tumor types and that, with the exception of GISTs, KIT gene mutations are rare in immunohistochemically KIT-positive tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Cited by
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Beadling, C., Jacobson-Dunlop, E., Hodi, F. S., Le, C., Warrick, A., Patterson, J., Town, A., Harlow, A., Cruz, F., Azar, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0575 · Cited by 646
Miettinen, M., & Lasota, J. (2005) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/01.pai.0000173054.83414.22 · Cited by 556
Heinrich, M. C., McArthur, G. A., Demetri, G. D., Joensuu, H., Bono, P., Herrmann, R., Hirte, H., Cresta, S., Koslin, D. B., Corless, C. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0717 · Cited by 318
Self-citationKIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
Lasota, J., & Miettinen, M. (2006) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.08.006 · Cited by 291
Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies
Dodd, R. L., & Slevin, N. J. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2006.01.001 · Cited by 256
Metadata
- Authors
- Went, P. T., Dirnhofer, S., Bundi, M., Mirlacher, M., Schraml, P., Mangialaio, S., Dimitrijevic, S., Kononen, J., Lugli, A., Simon, R., & Sauter, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-11-15
- Volume
- 22
- Issue
- 22
- Pages
- 4514-4522
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131397638
- Cited by
- 222
- References
- 1
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of KIT Expression in Human Tumors. https://app.cochat.ai/papers/10.1200/jco.2004.10.125
- The paper
- Went, P. T., Dirnhofer, S., Bundi, M., Mirlacher, M., Schraml, P., Mangialaio, S., Dimitrijevic, S., Kononen, J., Lugli, A., Simon, R., & Sauter, G. (2004). Prevalence of KIT Expression in Human Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.10.125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.